Best Biotech Stocks for Options Trading
Summary
Biotech stocks consistently have the highest implied volatility in the equity market. FDA approval decisions, clinical trial results, and pipeline updates create binary events that inflate IV to 80-150%+. For options sellers, this means premiums of 5-10% monthly on many biotech names. The risks are equally extreme — a failed drug trial can send a biotech stock down 50-80% overnight. The key is trading large-cap biotechs with diversified pipelines and using defined-risk strategies.
Key Takeaways
Large-cap biotechs (ABBV, AMGN, GILD, BIIB) offer moderate IV with diversified revenue — safer for covered calls. Mid-cap biotechs (MRNA, EXAS, IONS) have higher IV and larger earnings swings. Small-cap biotechs (pre-revenue) are essentially binary bets — avoid selling naked options on these. The XBI (Biotech ETF) provides diversified biotech exposure with 25-35% IV and reasonable options liquidity.
---
The biotech sector is options paradise — if you know where to look and how to size your bets. IV in the sector ranges from 25% (large-cap pharma) to 150%+ (small-cap clinical stage), creating a spectrum of risk-reward profiles.
Large-Cap Biotech: The Safe Plays
| Stock | Price | 30-Day IV | Pipeline Risk | CC Monthly % |
These companies have approved drugs generating billions in revenue. A single drug failure doesn't threaten the company. Covered calls on ABBV or AMGN feel similar to covered calls on any other blue-chip stock.
Best pick: ABBV. Strong 3.6% dividend yield plus 1.2% monthly covered calls equals ~18% total annual yield. The company's Humira biosimilar transition is well-managed, and Skyrizi/Rinvoq are growing rapidly.
Mid-Cap Biotech: Higher Premium, Higher Risk
MRNA (Moderna) is the most interesting mid-cap play. Post-COVID, the stock dropped from $400+ to ~$45, and the market debates whether its mRNA pipeline (cancer vaccines, flu, RSV) will generate enough revenue to justify the current valuation. That debate keeps IV at 55%, generating 3.5% monthly covered call premiums.
XBI: The Diversified Play
If you want biotech exposure without single-stock risk, XBI (the SPDR S&P Biotech ETF) holds 130+ biotech stocks with equal weighting. IV runs 25-35%, generating 1.2-1.5% monthly covered call premiums.
At ~$95 per share ($9,500 per 100 shares), XBI is accessible for mid-sized accounts. The equal-weight structure means no single drug failure devastates the position.
Risk Management Rules
Never sell naked puts on small-cap biotech. A stock going from $30 to $5 on a failed trial means a $2,500 loss per naked put. Use put credit spreads instead.
Position size by pipeline diversity. Large-cap biotech with 10+ approved drugs: up to 10% of portfolio. Mid-cap with 2-3 approved drugs: 5%. Pre-revenue biotech: 2% maximum, spreads only.
Avoid holding through binary events. Close positions 3-5 days before PDUFA dates, major clinical trial readouts, or earnings with significant pipeline updates.
OptionsPilot displays IV rank and upcoming catalyst dates for biotech stocks, helping you time your premium-selling entries for maximum income while avoiding binary event risk.